铁死亡在胰腺癌吉西他滨耐药中的研究进展  

Research progress of ferroptosis in gemcitabine resistance in pancreatic cancer

作　　者：李响 田国锋[4] 肖宛儒[4] 郝靓 LI Xiang;TIAN Guofeng;XIAO Wanru;HAO Liang(Department of Chemistry,School of Forensic Medicine,China Medical University,Shenyang 110122,China;Liaoning Province Key Laboratory of Forensic Bio-evidence Sciences,Shenyang 110122,China;China Medical University Center of Forensic Investigation,Shenyang 110122,China;The First Department of Clinic,China Medical University,Shenyang 110000,China;不详)

机构地区：[1]中国医科大学法医学院化学教研室,沈阳110122 [2]辽宁省法医学生物证据重点实验室,沈阳110122 [3]中国医科大学司法鉴定中心,沈阳110122 [4]中国医科大学第一临床学院,沈阳110000

出　　处：《实用医学杂志》2023年第12期1571-1576,共6页The Journal of Practical Medicine

基　　金：国家自然科学基金青年科学基金项目(编号:82103693);中国博士后科学基金(编号:2022M713486);辽宁省教育厅科学研究经费项目(面上项目)(编号:LJKZ0787);辽宁省科学技术计划项目(编号:2022⁃YGJC⁃32);2023年中国医科大学“大创计划”项目。

摘　　要：胰腺癌是生存率最低和预后最差的消化道肿瘤之一。大多数患者确诊时已失去手术根治切除的机会,并在应用一线化疗药物吉西他滨(GEM)治疗过程中出现耐药性,进一步降低治疗效果。近年来,铁死亡作为一种新型铁依赖型细胞程序性死亡形式,其调控机制也被广泛研究并应用于胰腺癌的治疗中。有实验研究表明诱导胰腺癌细胞铁死亡可有效降低其对化疗药物的耐药性。本文综述了铁死亡在胰腺癌吉西他滨耐药中的研究进展,旨在为研究铁死亡与胰腺癌治疗提供新的思路和方向。Pancreatic cancer(PC),as one of the digestive tract tumors with the lowest survival rate and the worst prognosis,is known as the“king of cancers”.Most patients have lost the opportunity for radical resection at diagnosis and have developed resistance to gemcitabine(GEM),the first⁃line chemotherapy agent,further reducing the effectiveness of treatment.In recent years,ferroptosis a new type of iron⁃dependent cell programmed death,and its regulatory mechanism has been widely studied and applied in the treatment of pancreatic cancer.Ex⁃perimental studies have shown that inducing ferroptosis in pancreatic cancer cells can effectively reduce their resis⁃tance to chemotherapy drugs.In this paper,the role of ferroptosis in gemcitabine resistance of pancreatic cancer were reviewed,aiming to provide new ideas and directions for the study of the treatment of pancreatic cancer based on ferroptosis.

关 键 词：铁死亡 胰腺癌 吉西他滨耐药 

分 类 号：R735.9[医药卫生—肿瘤]